Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy

• Main Authors: Ping Huang (Author), Jia-huan Huang (Author), Ya-bing Zheng (Author), Wen-ming Cao (Author), Xi-ying Shao (Author), Jun-qing Chen (Author), Yuan Huang (Author), Guang-liang Li (Author), K Sharma (Author), Huan-huan Zhou (Author), Xiao-jia Wang (Author), Hong-chuan Jin (Author), Zhan-hong Chen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Cardiotoxicity associated with the sequential use of anthracyclines followed by trastuzumab is common in adjuvant therapy of patients with HER2-positive early breast cancer (eBC). However, the cardiac safety of trastuzumab concurrent with pegylated liposomal doxorubicin (PLD) is relative...